What is Concortis Biosystems?
Concortis Biosystems is a biopharmaceutical company dedicated to the development of next-generation antibody-drug conjugates (ADCs) aimed at addressing critical unmet medical needs. The company currently boasts approximately 20 ADC programs in preclinical development, with plans to initiate four clinical trials in 2023. Its core mission is to establish itself as a leader in creating 'first-in-class' and 'best-in-class' ADCs, positioning it at the forefront of innovative cancer therapeutics.
How much funding has Concortis Biosystems raised?
Concortis Biosystems has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Concortis Biosystems
PPP
Public-Private Partnership
What's next for Concortis Biosystems?
The substantial late-stage funding indicates Concortis Biosystems is poised for significant scaling and clinical progression. This strategic investment will likely accelerate the advancement of its robust preclinical pipeline into clinical trials, potentially bringing novel ADC therapies to patients sooner. The company's focus on 'first-in-class' and 'best-in-class' ADCs suggests a strategy centered on differentiated therapeutic approaches, aiming to capture a leading market position in targeted oncology treatments.
See full Concortis Biosystems company page
